Honours

Awards

• ‘Professor Anupam Sengupta Memorial Medal’ for academic excellence in Pharmaceutical Chemistry in M. Pharm awarded by Jadavpur University, India.
• ‘Best Oral Presentation Award of ICCE, Thailand’ in International Congress of Chemistry and Environment Conference (ICCE) at Ubonrathchathani, Thailand.
• National Doctoral Fellowship (NDF) awarded by All India Council for Technical Education (AICTE), India.
• UGC Research Fellowship in Science for Meritorious Students awarded by University Grant Commission (UGC), India.
• UGC Scholarship awarded by University Grant Commission (UGC), India.

Publications

• Development and validation of a high throughput LC-MS/MS method for simultaneous quantitation of pioglitazone and telmisartan in rat plasma and its application to a pharmacokinetic study. Journal of Pharmaceutical Analysis, 2017. 7; 381–387.
  Impact Factor: 14.026.
• Development of a simple excel-based tool for surrogate peptide selection in mass spectrometry based targeted proteomics. Journal of Pharmaceutical and Biomedical Analysis. 2023. 222, 115105.
  Impact Factor: 3.571.
• LC-QQQ-MS based intracellular quantification of bictegravir in peripheral blood mononuclear cells and plasma. Analytical Biochemistry, 2023. 667, 115084.
  Impact Factor: 3.191.
• Stimuli-responsive nanotherapeutics for treatment and diagnosis of stroke. Pharmaceutics, 2023, 15, 1036.
  Impact Factor: 6.525.
• Degradation kinetics and characterization of major degradants of binimetinib employing liquid chromatography-high resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2022. 215, 114753.
  Impact Factor: 3.571.
• LC/Q-TOF MS and LC/QQQ MS based bioanalysis of a new ferrocene derivative as a potential anticancer lead with promising drug-like characteristics. Journal of Chromatography B, 2022. 1210, 123469.
  Impact Factor: 3.318.
• Cutting-edge strategies and critical advancements in characterization and quantification of metabolites concerning translational metabolomics. Drug Metabolism Reviews. 2022, 54 (4), 401-426.
  Impact Factor: 6.984.
• Engineering immunity via skin-directed drug delivery devices. Journal of Controlled Release. 2022, 345, 385-404.
  Impact Factor: 11.467.
• Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: A needful consideration towards modern anticancer drug discovery. Drug Metabolism Reviews. 2022. 54(2),101-119.
  Impact Factor: 6.984.
• A critical review on advancement in analytical strategies for the quantification of clinically relevant biological transporters. Critical Reviews in Analytical Chemistry, 2022. 52(7), 1557–1571.
  Impact Factor: 5.686.
• Advancement in analytical strategies for quantification of biomarkers with a special emphasis on surrogate approaches. Critical Reviews in Analytical Chemistry, 2022. https://doi.org/10.1080/10408347.2022.2035210.
  Impact Factor: 5.686.
• Critical strategies to pinpoint carryover problems in liquid chromatography-mass spectrometry: a systematic direction for their origin identification and mitigation. Microchemical Journal. 2022. 179, 107464.
  Impact Factor: 5.304.
• Systematic strategies for degradation kinetic study of pharmaceuticals: an issue of utmost importance concerning current stability analysis practices. Journal of Analytical Science and Technology. 2022, 13(7), 1-13.
  Impact Factor: 3.568.
• Current progress in preservative-free topical ophthalmic formulations. Journal of Drug Delivery Science and Technology. https://doi.org/10.1016/j.jddst.2022.103996. 2022.
  Impact Factor: 5.062.
• Bioanalysis by LC-MS/MS and preclinical pharmacokinetic interaction study of ribociclib and oleanolic acid. Bioanalysis, 2022. 14(15), 1051-1065. Impact Factor: 2.695.
• High resolution mass spectrometry driven metabolite profiling of baricitinib to report its unknown metabolites and step-by-step reaction mechanism of metabolism. Rapid Communications in Mass Spectrometry. 2022. 36, e9385. Impact Factor: 2.586.
• Hot stage microscopy based method for determination of particle size in reverse engineering: establishment of a platform technology employing carvedilol as a model drug. Current Analytical Chemistry. 2022. 10.2174/1573411018666220820095257.
  Impact Factor: 2.374.
• Surrogate peptide selection and internal standardization for accurate quantification of endogenous proteins. Bioanalysis, 2022. 14(13):949-961. Impact Factor: 2.695.
• LC-Q/TOF-HRMS and NMR based structural characterization of the major photodegradation impurity of Difluprednate. Chromatographia, 2022. 85, 605–615.
  Impact Factor: 2.213.
• LC-MS/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction. Bioanalysis, 2022. 14(2), 75-86.
  Impact Factor: 2.695.
• UHPLC–Q-TOF–MS/MS-based metabolite profiling of duvelisib and establishment of its metabolism mechanisms. Biomedical Chromatography. 2022, 36, e5314, 1-11.
  Impact Factor: 1.911.
• Emerging ROS‐modulating technologies for augmentation of the wound healing process. ACS omega. 2022. 7, 35, 30657–30672.
  Impact Factor: 4.132.
• Establishment of A Rapid and Highly Sensitive Reverse-Phase High-Performance Liquid Chromatography Based Analytical Assay Method for Duvelisib. Indian Journal of Pharmaceutical Education and Research, 2022, 56(1), 287-295.
  Impact Factor: 0.843.
• Mechanism of capmatinib degradation in stress conditions including degradation product characterization by UPLC-Q-TOF-MS and stability indicating analytical method development. Rapid Communications in Mass Spectrometry, 2023. 37:e9417. Impact Factor: 2.586.
• Assessment of metabolic stability, pharmacokinetics by LC-MS/MS and establishment of safe dose of IMID-2, a novel anticancer molecule under drug discovery. Biomedical Chromatography. 2023, e5618, 1-8.
  Impact Factor: 1.911.
• A comprehensive review on assessment and key control strategies for impurities in drug development with a special emphasis on postmarketing surveillance. Journal of Pharmaceutical Innovation. 2021. DOI: https://doi.org/10.1007/s12247-021-09607-9.
  Impact Factor: 2.538.
• A systematic UHPLC-Q-TOF-MS/MS based analytical approach for characterization of flibanserin metabolites and establishment of biotransformation pathway. Journal of Chromatography B, 2021, 1185, 123011.
  Impact Factor: 3.318.
• Recent Advancements and Future submissions of Silica Core-Shell Nanoparticles. International Journal of Pharmaceutics. 2021, 609, 121173.
  Impact Factor: 6.510.
• Innovation in strategies for sensitivity improvement of chromatography and mass spectrometry based analytical techniques. Critical Reviews in Analytical Chemistry, 2021. doi:10.1080/10408347.2021.1969887.
  Impact Factor: 5.686.
• Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis. Drug Discovery Today. 2021. 26(10), 2315-2328.
  Impact Factor: 8.369.
• Biosimilars accessible in the market for the treatment of cancer. Journal of Controlled Release. 2021, 336, 112-129.
  Impact Factor: 11.467.
• A mechanistic explanation on degradation behavior of flibanserin for identification and characterization of its potential degradants using LC-DAD/ESI/APCI-Q-TOF-MS/MS. Microchemical Journal. 2021, 167, 106281.
  Impact Factor: 5.304.
• Investigation of the impact of grapefruit juice, pomegranate juice and tomato juice on pharmacokinetics of brexpiprazole in rats using UHPLC-QTOF-MS. Biomedical Chromatography. 2021. 35(11), e5201.
  Impact Factor: 1.911.
• Emerging roles and biopharmaceutical applications of milk derived exosomes. Journal of Drug Delivery Science and Technology. 2021, 64, 102577.
  Impact Factor: 5.062.
• Advancements in practical and scientific bioanalytical approaches to metabolism studies in drug development. Bioanalysis, 2021. 13(11), 913–930.
  Impact Factor: 2.695.
• Innovation in bioanalytical strategies and in vitro drug–drug interaction study approaches in drug discovery. Bioanalysis, 2021. 13(6), 513–532. Impact Factor: 2.695.
• Identification and structural characterization of potential degraded impurities of ribociclib by time of flight -tandem mass spectrometry,and their toxicity prediction. Journal of Pharmaceutical and Biomedical Analysis. 2021, 197, 113933.
  Impact Factor: 3.571.
• Metabolite profiling of IMID-2, a novel anticancer molecule of piperazine derivative: In silico prediction, in vitro and in vivo metabolite characterization using UPLC–QTOF–MS/MS. Biomedical Chromatography. 2021, 35, e5082.
  Impact Factor: 1.911.
• Quantitation of Pregabalin by HPLC-UV Method using Ninhydrin Derivatization: Development and Validation. Current Pharmaceutical Analysis. 2021, 17(1), 165-171.
  Impact Factor: 0.743.
• LC-Q-TOF-MS driven identification of potential degradation impurities of venetoclax, mechanistic explanation on degradation pathway and establishment of a quantitative analytical assay method. Journal of Analytical Science and Technology, 2020. 11 (54), 1-13.
  Impact Factor: 3.568.
• Technological advancement in dry blood matrix microsampling and its clinical relevance in quantitative drug analysis. Bioanalysis, 2020, 12 (20), 1483–1501.
  Impact Factor: 2.695.
• Target Specific Intracellular Quantification of Etoposide by Quadrupole-Time of Flight based Mass Spectroscopic Method. Journal of Chromatography B, 2020, 1152, 122233.
  Impact Factor: 3.318.
• Challenges and strategies for quantification of drugs in the brain: current scenario and future advancement. Critical Reviews in Analytical Chemistry, 2022, 52 (1), 93-105.
  Impact Factor: 5.686.
• Simultaneous quantification of abemaciclib and letrozole in rat plasma: method development, validation and pharmacokinetic application, Biomedical Chromatography, 2020, 34, e4825.
  Impact Factor: 1.911.
• Time of flight mass spectrometry based in vitro and in vivo metabolite profiling of ribociclib and their toxicity prediction. Journal of Chromatography B, 2020, 1147, 122142.
  Impact Factor: 3.318.
• Mass spectrometry based rapid quantitative bioanalysis of flibanserin; pharmacokinetic and brain tissue distribution study. Journal of Analytical Toxicology, 2020, 44 (6), 559–569.
  Impact Factor: 3.220.
• Amalgamation of Stress Degradation and Metabolite Profiling in Rat Urine and Feces for Characterization of Oxidative Metabolites of Flibanserin using UHPLCQ-TOF-MS/MS, H/D Exchange and NMR Technique. Journal of Chromatography B, 2020, 1139, 121993.
  Impact Factor: 3.318.
• Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products. International Journal of Pharmaceutics. 2020, 576, 119018.
  Impact Factor: 6.510.
• Bioanalysis and Quadrupole-Time of Flight-Mass Spectrometry Driven In Vitro Metabolite Profiling of a New Boronic Acid Based Anticancer Molecule. Journal of Chromatographic Science. 2020, 58(9), 796-803.
  Impact Factor: 1.555.
• Development and Validation of a Simultaneous Bioanalytical Method for Methotrexate, Sulfasalazine and Hydroxychloroquine in Rat Plasma following Single Step Protein Precipitation Technique. Indian Journal of Pharmaceutical Education and Research, 2020, 54 (2), S358-S367.
  Impact Factor: 0.843.
• Advancement in analytical strategies for quantification of the multifaceted nitroxidative stress biomarker 3-Nitrotyrosine in biological matrices. Critical Reviews in Analytical Chemistry, 2020, 50 (3), 265-289.
  Impact Factor: 5.686.
• Reactive metabolites: generation and estimation with electrochemistry based analytical strategy as an emerging screening tool. Current Analytical Chemistry, 2020, 16 (7), 811-825.
  Impact Factor: 2.374.
• 3-Nitrotyrosine: a versatile oxidative stress biomarker for major neurodegenerative diseases. International Journal of Neuroscience, 2020, 130 (10), 1047–1062.
  Impact Factor: 2.590.
• Current Standing and Technical Guidance on Intracellular Drug Quantification: A New Site Specific Bioavailability Prediction Approach. Critical Reviews in Analytical Chemistry, 2020, 50 (1), 50-61.
  Impact Factor: 5.686.
• Development and validation of a stability indicating high performance liquid chromatography method for trimethobenzamide. Brazilian Journal of Pharmaceutical Sciences. 2020. 56, e18817.
  Impact Factor: 1.214.
• Simultaneous bioanalysis and pharmacokinetic interaction study of Acebrophylline, Levocetirizine and Pranlukast in Sprague Dawley rat. Biomedical Chromatography, 2019, 33: e4672.
  Impact Factor: 1.911.
• Edaravone-caffeine combination for the effective management of rotenone induced Parkinson’s disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression. Neuroscience Letters, 2019, 711, 134438.
  Impact Factor: 3.197.
• A bioanalytical method for eliglustat quantification in rat plasma. Journal of Chromatographic Science, 2019. 57(7): 600-605.
  Impact Factor: 1.618.
• An exploration of advancement in analytical methodology for quantification of anticancer drugs in biomatrices. Analytical Sciences, 2019. 35(7):719-732.
  Impact Factor: 2.081.
• Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. International Journal of Pharmaceutics, 2019. 565; 258-268.
  Impact Factor: 6.510.
• Paradigm shift in the arena of sample preparation and bioanalytical approaches involving liquid chromatography mass spectroscopic technique. Analytical Sciences, 2019. 35 (10), 1069-1082.
  Impact Factor: 1.967.
• Current direction and advancement in analytical sample preparation techniques with special emphasis on bioanalysis: A technical guidance for picking the appropriate approach. Bioanalysis, 2019. 11 (4).
  Impact Factor: 2.695.
• Establishment of a quantitative bioanalytical method for an acetylcholinesterase inhibitor Ethyl 3-(2-(4-fluorophenyl) amino)-4-phenylthiazol-5-yl)-3-oxopropanoate including its physicochemical characterization and in vitro metabolite profiling using Liquid Chromatography-Mass Spectrometry. Journal of Chromatography B, 2018. 1096; 214–222.
  Impact Factor: 3.318.
• Drug development and bioanalytical method validation for a novel anticancer molecule, 4-(Dimethylamino)-2-(p-tolylamino) thiazole-5-carbonitrile. Drug Development Research, 2018. 79, 391-399.
  Impact Factor: 5.004.
• Formulation of Dispersed Gliclazide Powder in Polyethylene Glycol-Polyvinyl Caprolactam-Polyvinyl Acetate Grafted Copolymer Carrier for Capsulation and Improved Dissolution. Indian Journal of Pharmaceutical Education and Research, 2018. 52(4s2); S210-S219.
  Impact Factor: 0.843.
• Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. International Journal of Pharmaceutics, 2018. 543 (1–2); 328-344.
  Impact Factor: 6.510.
• Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination. Regulatory Toxicology and Pharmacology, 2017. 91; 151–158.
  Impact Factor: 3.598.
• Chemical constituents and medical benefits of Plantago major. Biomedicine & Pharmacotherapy. 2017; 96; 348-360.
  Impact Factor: 7.419.
• Development of a binary carrier system consisting polyethylene glycol 4000 ‐ ethyl cellulose for ibuprofen solid dispersion. International Journal of Pharmaceutical Investigation, 2017; 7; 142-148.
• Stability indicating RP-HPLC method for simultaneous quantitation of tramadol and aceclofenac in presence of their major degradation products: method development and validation. Journal of Liquid Chromatography & Related Technology, 2017. 40 (17); 887–893.
  Impact Factor: 1.467.
• Development, validation and pharmacokinetic application of a simple and robust RP-HPLC method for quantitation of raloxifene in rat plasma. Latin American Journal of Pharmacy, 2017; 36(9); 1901-1907.
  Impact Factor: 0.229.
• Incorporation of Carbopol to Palm Olein Based Analgesic Cream: Effect on Formulation Characteristics. Latin American Journal of Pharmacy, 2017. 36 (11); 2144-52.
  Impact Factor: 0.229.
• Potential and future scope of nanoemulgel formulation for topical delivery of lipophilic drugs. International Journal of Pharmaceutics, 2017. 526 (1-2); 353–365.
  Impact Factor: 6.510.
• Recent update on nanoemulgel as topical drug delivery system. Journal of Pharmaceutical Sciences. 2017; 106; 1736-1751.
  Impact Factor: 3.784.
• Pharmacokinetic and Pharmacodynamic Features of Nanoemulsion Following Oral, Intravenous, Topical and Nasal Route. Current Pharmaceutical Design, 2017;23: 2504-2531.
  Impact Factor: 3.310.
• Mucoadhesive polymers and their mode of action: a recent update. Journal of Applied Pharmaceutical Science. 2017; 7(5), 195-203.
• An experimental evaluation of adaptogenic potential of standardized Epipremnum aureum leaf extract. Journal of Pharmacy and Bioallied Sciences. 2017; 9; 88-93.
• Effect of ethanolic extract of Pericampylus glaucus (Lam) Merr on biochemical parameters in Sprague-Dawley rats with high fats diets. Journal of Coastal Life Medicine. 2017; 5(5): 219-223.
• Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat. Regulatory Toxicology and Pharmacology, 2016, 81; 155-161.
  Impact Factor: 3.598.
• Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view. Drug Delivery. 2016; 23(9); 3639–3652.
  Impact Factor: 6.819.
• Stability indicating RP-HPLC method for simultaneous determination of aspirin and clopidogrel in dosage form. Malaysian Journal of Analytical Sciences. 2016; 20(2); 247-257.
• . Effect of Pericampylus glaucus Lam Merr on plasma glucose concentration and lipid profile in Streptozotocin-induced diabetic rats. Bangladesh Journal of Pharmacology. 2016; 11; 200-205.
  Impact Factor: 1.143.
• Sustained release in situ gelling systems of metformin: formulation development. Pharmawave. 2016; 9 (16); 1-6.
• Phytochemical investigation and antioxidant screening of crude leaves extract from Epipremnum aureum. International Journal of Pharmacognosy and Phytochemical Research. 2015; 7(4); 684-689.
• Toxicological investigation of ethanolic extract of Epipremnum aureum in rodents. Journal of Applied Pharmaceutical Science. 2015; 5(2); 057-061.
• Evaluation of ethanolic extract of pericampylus glaucus (lamk.) merr for total phenolic, total flavonoids contents and in-vitro anti -oxidant activity. International Journal of Pharmacognosy and Phytochemical Research. 2015; 7(4); 677-683.
• Evaluation of the acute and sub-acute toxicity of the ethanolic extract of Pericampylus glaucus lamk merr in mice. Journal of Acute Disease. 2015; 4(4); 303-308.
• Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. Regulatory Toxicology and Pharmacology, 2012, 62, 7-15.
  Impact Factor: 3.598.
• Development and Validation of a LC-ESI-MS/MS Method for Simultaneous Quantitation of Olmesartan and Pioglitazone in Rat Plasma and Its Pharmacokinetic Application. Biomedical Chromatography, 2010, 24, 1342-1349.
  Impact Factor: 1.911.
• Stability-Indicating RP-HPLC Method for Simultaneous Determination of Olmesartan medoxomil and Pioglitazone in Fixed Dose Combination Tablet Dosage Form. Asian Journal of Chemistry, 2010, 22(8), 6471-6479.
• Twenty-eight Days Repeated Oral Dose Toxicity Study of Gemifloxacin in Wistar Albino Rats. Regulatory Toxicology and Pharmacology, 2010, 58, 196-207.
  Impact Factor: 3.598.
• Bioequivalence Study of a Fixed Dose Combination Tablet containing Rabeprazole and Diclofenac Sodium in Healthy Indian Subjects. Drug Research, 2010, 60 (8), 506-509.
• Stability-Indicating HPLC Method for the Determination of Oxcarbazepine in Pharmaceutical Formulation. Asian Journal of Chemistry, 2010; 22 (3), 2051-2057.
• LC–MS–MS development and validation for simultaneous quantitation of metformin, glimepiride and pioglitazone in human plasma and its application to a bioequivalence study. Chromatographia, 2009, 69 (11/12), 1243-1250.
  Impact Factor: 2.213.
• Development and Validation of a Highly Sensitive and Robust LC-ESI-MS/MS Method for Simultaneous Quantitation of Simvastatin Acid, Amlodipine and Valsartan in Human Plasma: Application to a Clinical Pharmacokinetic Study. Biomedical Chromatography, 2009, 23, 615-622.
  Impact Factor: 1.911.
• Development and Validation of a High-performance Liquid Chromatographic Method for Bioanalytical Application with Rimonabant. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 1009-1013.
  Impact Factor: 3.571.
• Rapid and Sensitive HPLC Method for Analysis of Gemifloxacin in Human Plasma. Chromatographia, 2009, 69(9-10), 853-858.
  Impact Factor: 2.213.
• Evaluation of Anticancer Activity of Some 1, 3, 4 Oxadiazole Derivatives. Indian Journal of Chemistry, Sec B, 2008; 47B, 460-462.
  Impact Factor: 0.456.
• Evaluation of Antibacterial and Antifungal Activity of Some 1, 3, 4 Oxadiazoles. Iranian Journal of Pharmacology and Therapeutics. 2008, 7(2), 165-167.
• Determination of Ranolazine in Human Plasma by LC-MS/MS and Its Application in Bioequivalence Study. Journal of Pharmaceutical and Biomedical Analysis, 2008; 48, 1404-1410.
  Impact Factor: 3.571.
• Antidiabetic and In Vivo Antioxidant Activity of Ethanolic Extract of Bacopa monnieri Linn. Aerial Parts: A Possible Mechanism of Action. Iranian Journal of Pharmaceutical Research, 2008; 7 (1), 61-68.
  Impact Factor: 1.962.
• Evaluation of Hepatoprotective and Antioxidant Activity of Ichnocarpus frutescens (Linn.) R.Br. on Paracetamol-induced Hepatotoxicity in Rats. Tropical Journal of Pharmaceutical Research, Sep 2007; 6(3), 755-765.
  Impact Factor: 0.523.
• Antidiabetic, Antioxidant and Antihyperlipidemic Status of Heliotropium zeylanicum Extract on Streptozotocin-induced Diabetes in Rats. Biological & Pharmaceutical Bulletin, 2006; 29(11), 2202-2205.
  Impact Factor: 2.264.

• Book Chapters
• Chapter 12 – Drug–drug interactions and their implications on the pharmacokinetics of the drugs. Pharmacokinetics and Toxicokinetic Considerations, Volume 2 in Advances in Pharmaceutical Product Development and Research, 2022, 291-322.
• Chapter 8 – New emerging technologies for genetic toxicity testing. Pharmacokinetics and Toxicokinetic Considerations, Volume 2 in Advances in Pharmaceutical Product Development and Research, 2022, 175-219.
• Chapter 5 – Understanding the concept of signal toxicity and its implications on human health.Pharmacokinetics and Toxicokinetic Considerations, Volume 2 in Advances in Pharmaceutical Product Development and Research, 2022, 99-116.
• Chapter 17 – Drug toxicity and forensic pharmacokinetics.Pharmacokinetics and Toxicokinetic Considerations, Volume 2 in Advances in Pharmaceutical Product Development and Research, 2022, 425-486.
• Chapter 26 – Toxicokinetic and toxicodynamic considerations in drug research. Pharmacokinetics and Toxicokinetic Considerations, Volume 2 in Advances in Pharmaceutical Product Development and Research, 2022, 751-776.
• Chapter 8 – Pharmacokinetic characterization of drugs and new product development. Biopharmaceutics and Pharmacokinetics Considerations, Volume 1 in Advances in Pharmaceutical Product Development and Research, 2021, 195-277.
• Pharmacokinetic and sub-chronic toxicity study of a fixed dose combination and a sustained release tablet. IIUM Press, International Islamic University Malaysia, Kuala Lumpur, Malaysia, 2017, ISBN 978-967-418-701-9.

Research Lab

Research Activities

1. MRM Proteomics

2. Development of Stability Indicating Assay Method

3. Lipid Analysis

4. Dried Blood Spot Analysis

5. Cleaning Validation: Swab Collection from Glass Plate

Prev Slide

Next Slide

play

stop

Research Scholars

Student Details

Tarang Jadav

Ph.D Scholar (2019)
Understanding the modulatory potential of drugs on transporters’ expression (p-gp, MRP1 & BCRP) and its impact on drug-drug interaction.
Google scholar profile

Niraj Rajput

Ph.D Scholar (2020)
Evaluating PXR induced/Drug-Metabolizing Enzyme and Transporter-Mediated drug-drug interaction potential.

Megha Pillai

Ph.D Scholar (2021)
Establishing a dissolution safe space and IVIVC for BCS class II and class IV drug products through PBPK/PBBM modeling

Pooja Dhakne

Ph.D Scholar (2021)
Exploring the therapeutic role of amino acids and its effects on differentially expressed mitochondrial proteins involved in stroke.

Jinal Ajabiya

Ph.D Scholar (2022)
Proteomics/Bioanalysis/Pharmacokinetics

Nasir Khan

Ph.D Scholar (2022)
Proteomics/Bioanalysis/Pharmacokinetics

Dr. Amit Sahu

Ph.D (2017-2022)

Dr. Manish Sharma

Ph.D (2015-2021)

Arnav Golhar

M.S. Student (2021-2023)

Karuna Chandnani

M.S. Student (2021-2023)

Nachiket Kathar

M.S. Student (2021-2023)

Prasad Chavan

M.S. Student (2021-2023)

Ratik Bulbule

M.S. Student (2021-2023)

Sneha Kaareddy

M.S. Student (2021-2023)

Vishal Borale

M.S. Student (2021-2023)

Ashish Jogpethe

M.S. Student (2020-2022)

Dhiraj Bhangare

M.S. Student (2020-2022)

Megha Rachmale

M.S. Student (2020-2022)

Mrunal Palshikar

M.S. Student (2020-2022)

Sonam Mishra

M.S. Student (2020-2022)

Anuradha Reddy

M.S. Student (2019-2021)

Deeki Doma

M.S. Student (2019-2021)

Dipali Sonawane

M.S. Student (2019-2021)

Fatema Soni

M.S. Student (2019-2021)

Mustafa Modiwala

M.S. Student (2019-2021)

Nikita Tapkir

M.S. Student (2019-2021)

S. Pranush Kumar

M.S. Student (2019-2021)

Akhila Pyaram

M.S. Student (2018-2020)

Dhruvisha Pokar

M.S. Student (2018-2020)

Jayshri Deore

M.S. Student (2018-2020)

Madhuri Rampilla

M.S. Student (2018-2020)

Niraj Panday

M.S. Student (2018-2020)

Niraj Rajput

M.S. Student (2018-2020)

Ajitha Reddy

M.S. Student (2017-2019)

Dayaraju Adey

M.S. Student (2017-2019)

Pooja Dhakne

M.S. Student (2017-2019)

Maria Bandookwala

M.S. Student (2017-2019)

Tarang Jadav

M.S. Student (2017-2019)

Siddhaarth Nagamalli

M.S. Student (2017-2019)

Sonali Jain

M.S. Student (2017-2019)

Aarati Dilip Zagade

M.S. Student (2016-2018)

Chevuri Venkata Krishna Reddy

M.S. Student (2016-2018)

Narayana Swamy

M.S. Student (2016-2018)

G Navitha Reddy

M.S. Student (2016-2018)

Nemani Kavya Sri

M.S. Student (2016-2018)

Nripendra Madhab Biswas

M.S. Student (2016-2018)

Priyanka Lohar

M.S. Student (2016-2018)

Expertise

Achievements

NewsFlash

Prev Slide

Next Slide

play

stop